OBJECTIVES: A single or dual-dose strategy for myocardial protection is attractive in long operations, in avoiding the need to interrupt the procedure to re-administer cardioplegia. We hypothesized that a single administration of Bretschneider histidine-tryptophan-ketoglutarate (HTK) crystalloid solution (Custodiol) offers myocardial protection comparable with repeated tepid blood cardioplegia.
INTRODUCTION
Inadequate myocardial protection in long ischaemic periods followed by reperfusion is an issue of concern in cardiac surgery. Cardioplegic solutions improve the tolerance to ischaemia and reperfusion by preserving myocardial energy reserves, preventing osmotic and electrolyte imbalances and buffering acidosis. The cardioplegic solutions can be classified into two main groups. One is based on extracellular components with high potassium, magnesium and bicarbonate levels, while the other is based on intracellular electrolytes. Both have demonstrated beneficial effects as measured with the biochemical markers in biological models and in patients, although the latter option (intracellular composed solution) may appear more effective [1] .
Histidine-tryptophan-ketoglutarate (HTK) is a solution based on the intracellular level of electrolytes, proposed by Bretschneider in the 1970s [2] . Histidine, tryptophan, ketoglutarate and manitol act as buffers and improve high energy production via adenosine triphosphate during reperfusion, stabilize cell membranes and maintain osmotic regulation of the cell membrane. Several studies have shown the efficacy of the HTK solution based on biochemical markers or physiological evaluation in experimental models [3] [4] [5] . In recent years, HTK has been used as a multi-organ preservation solution as well as cardioplegia in cardiac surgery in several countries but not universally throughout the world.
A single-dose cardioplegia may be an attractive option in more complex cardiac procedures as re-administration of cardioplegia can disturb the technical flow of the operation. To our knowledge, no studies have directly compared the use of HTK and blood cardioplegia in a spectrum of complex cardiac surgical procedures. This is somewhat surprising given the high number of procedures performed worldwide with this cardioplegic solution. As such, the purpose of this study was to assess the safety of the HTK solution when compared with our standard tepid blood cardioplegia in complex cardiac procedures.
PATIENTS AND METHODS
We performed a retrospective review of a prospectively collected single-centre database containing all adult cardiac procedures performed from 1 January 2005 to 31 January 2011 at the Austin Hospital, a tertiary referral centre in metropolitan Melbourne, Australia. Data were prospectively compiled as part of Austin Hospital's contribution to Australasian Society of Cardiac and Thoracic Surgeons (ASCTS) database project.
The database records detailed patient demographics, preoperative risk factors, operative technique, postoperative hospital course and clinical outcome including 30-day or in-hospital morbidity and mortality. Data were collected prospectively using an agreed data set and definitions as part of the clinical care by surgeons, perfusionists, resident medical officers and database managers. Thirty-day mortality information is obtained by telephone contact with patients, family members or the medical practitioner, while the 30-day morbidity data are recorded if occurring prior to discharge or upon any subsequent re-presentation to hospital within 30 days. The entire database is regularly subject to external audit measures with recently reported overall data accuracy of 97.4% [6] . Individual patient consent was waived for this study as the institutional review board of each participating unit in the ASCTS database had previously approved the use of this database for research.
Operations in which Custodiol was used as cardioplegia were identified and compared with the remainder, all of whom received blood cardioplegia.
Surgical technique
Haemodynamic monitoring was carried out via an arterial line in the radial and/or femoral artery; the Swan-Ganz catheter via the internal jugular vein; urinary catheter and trans-oesophageal echocardiogram. Conventional general anaesthesia was used in all patients. Surgical approach was via median sternotomy.
The cardiopulmonary bypass (CPB) was established by an arterial cannula in the ascending aorta/aortic arch or femoral artery. Venous drainage was obtained via a two-stage cannula in the right atrium or bicaval cannulation through the superior and inferior vena cavae or femoral vein.
Under CPB and aortic cross-clamping, cardioplegic arrest was induced. In the HTK (Custodiol; Koehler Chemi, AlsbachHaenlien, Germany) group, systemic temperature was lowered to 28°C. Two-thirds of the HTK solutions at 4°C were given in an antegrade fashion at an initial perfusion pressure of 80-100 mmHg. When the myocardium was at standstill, the perfusion pressure was maintained at 40-60 mmHg. The remaining one-third was administered via a retrograde route. A single dose of 25 ml/kg over 5-7 min was given in all cases. A second halfdose was given after 3 h of cross-clamping or if any electrical or mechanical activity appeared before this period. This was to flush and cool the myocardium.
In the blood-cardioplegia group, systemic temperature was reduced to 34°C, or lower in the case of aortic arch operations.
One litre of tepid (28°C) blood induction cardioplegia, mixed at 4:1 (blood: induction cardioplegic solution) was given with two-thirds through the antegrade and one-third through the retrograde route. Tepid blood maintenance cardioplegia, mixed at 4:1 (blood: maintenance cardioplegic solution), was repeated every 15-20 min using both routes (Table 1) . A 'hot shot' (warm blood) retrograde dose was given just before the myocardium reperfusion.
Tepid blood cardioplegia was our standard method as we have been using this for many years. We started using Custodiol in more complex cases from January 2009. The decision to use Custodiol was made by the surgeon, perfusionist and anaesthetist involved in the case, based on the accepted indications for its use in our institution. The indications for the use of Custodiol in our institution are comparable with the indications reportable in the literature. These include: mitral valve procedures, including minimally invasive, aortic procedures, redo operations, multiple valve procedures, trainee cases, anticipated difficult to repeat cardioplegia [such as a small right coronary artery in aortic valve replacement (AVR)].
Study endpoints
Our primary study endpoints, defined before the analysis, were eight serious early postoperative events. These were 30-day mortality, return to the operating theatre for any cause, myocardial infarction (MI), stroke, new renal failure, prolonged ventilation (>24 h), postoperative intra-aortic balloon pump (IABP) insertion and re-admission to hospital within 30 days. Furthermore, as secondary endpoints, we compared between groups, the proportion of patients experiencing postoperative new onset atrial fibrillation or flutter (AF) requiring treatment, heart block and ventricular tachycardia (VT) or fibrillation (VF) requiring cardioversion and/or IV amiodarone.
MI was defined as at least two of the following: cardiac enzyme elevation (creatinine kinase-myocardial band [CK-MB] > 30 U/l or troponin > 20 mg/l), new wall motion abnormalities and new Q waves on at least two serial electrocardiograms. New renal failure was defined as at least two of the following: serum creatinine increased to >0.2 mmol/l, doubling or greater increase 
in serum creatinine over the preoperative value and a new requirement for renal replacement therapy. We also examined a composite endpoint of 'mortality/any morbidity' which encompasses the events listed above.
Statistical analysis
Preoperative demographic and investigative data, operative variables and postoperative (30-day) mortality and morbidity were compared between the Custodiol and blood cardioplegia groups.
In an unmatched sample, categorical variables were expressed as frequencies and compared using Fisher's exact and Chi-squared tests. Continuous variables were expressed as mean ± standard deviation and compared using the unpaired t-test.
Propensity-score matching was performed to correct the potential bias associated with the usage of Custodiol. A propensityscore was generated for each patient in the standard fashion by performing a non-parsimonious logistic regression with the usage of Custodiol as the dependent variable. Baseline clinical and investigative variables which were expected to influence patient selection and postoperative outcomes were included (Table 2) . Albeit unconventional, we also attempted to match aortic crossclamp time. Although this variable is usually analysed as a 'result', we chose to match this variable so that the impact of the cardioplegia solution could be better isolated in statistical analyses. The c-statistic was calculated for the propensity model. Once generated, patients were matched one-to-one on their propensityscore without replacement using the 'greedy' matching method with a fixed caliper width of 0.02.
Following matching, standardized differences were used to assess the degree of baseline variable balance in the manner described by Austin [7] . A high degree of balance is generally reflected by a standardized difference of ≤10%; however, given the relatively smaller sample sizes of this study, we used ≤20% as a more reasonable cut-off for reflecting balance. In the matched sample, paired t-tests were used for continuous data, while McNemar's test-which compares discordance of two dichotomous outcomes-was used to compare categorical postoperative outcomes. Absolute numbers (percentages).
RESULTS
A total of 1900 cardiac surgical procedures were identified, of which 126 (7%) utilized Custodiol and 1774 (93%) blood cardioplegia as the primary cardioplegic agent. Table 2 displays the preoperative clinical and investigative characteristics across the two groups. There were numerous statistically significant differences between groups as shown. Table 3 displays the group comparisons for the early postoperative period. Of note, patients receiving Custodiol experienced a trend towards greater 30-day mortality (blood cardioplegia: 3% vs Custodiol 6%, P = 0.079) in addition to higher proportions of the combined any mortality/morbidity endpoint (blood cardioplegia: 33% vs Custodiol 47%, P < 0.001). The proportion of patients experiencing new onset AF (26 vs 25%, P > 0.99) and heart block (2.3 vs 4.0%, P = 0.22) was similar; however, patients in the Custodiol group were more likely to experience new-onset ventricular tachycardia or fibrillation (1.2 vs 4.0%, P = 0.029).
The propensity score model constructed performed well with a c-statistic of 0.93 (95% CI: 0.91-0.95). We were able to match 71 Custodiol cases one-to-one to those receiving blood cardioplegia, thus representing a 56% matching rate. Table 4 displays the preoperative and intraoperative profiles of the propensityscore matched groups. All baseline variables had a standardized difference of <20%, thus representing a reasonable degree of matching given the sample size. After propensity-score matching, preoperatively, 35% of patients were in New York Heart Association class III or IV, 31% had pulmonary hypertension, 8% were re-do operations, 8% had active endocarditis and mean EuroSCORE was 6.9. Furthermore, 27% had concomitant coronary artery bypass grafting (CABG) and AVR, 24% underwent aortic procedures, while 15% underwent a double valve procedure. Only 4% underwent isolated CABG and 28% isolated valve procedures. Table 5 displays the postoperative outcomes between the propensity-score matched patient groups. Of note, there were no statistically significant differences noted for any of the endpoints studied after propensity-score matching. In particular, the proportion of mortality (blood cardioplegia: 1% vs Custodiol 4%, P = 0.63) and mortality/morbidity (blood cardioplegia: 35% vs Custodiol: 39% P = 0.46) was similar between groups. After propensity-score matching, there were similar rates of new-onset AF (23 vs 25%, P = 0.83), heart block (9.9 vs 4.2%, P = 0.34) and VT/VF (2.8 vs 1.2%, P > 0.99).
DISCUSSION
Blood cardioplegia has been used as the standard to protect the myocardium. However, it must be repeated every 15-20 min and the surgical procedure is suspended during infusion. For the long and technically complex case-which is becoming ever more common in our centre's practice-an uninterrupted surgical field is desirable, making Custodiol an attractive option.
A single dose of the HTK solution appears adequate in protecting the myocardium for an extended period. The major advantages of the HTK solution for improving clinical outcomes are based on the buffer effect of histidine, which may enhance the efficiency of anaerobic glycolysis, while ketoglutarate acts as an intermediary in the Krebs cycle and is a precursor of nicotinamide adenine dinucleotide. Tryptophane stabilizes the cell membrane and the addition of mannitol decreases cellular oedema. Kresh et al. [8] noted that protein buffers such as histidine might be superior to bicarbonate in stabilizing intracellular pH and faciliating recovery of post-ischaemic biochemical and mechanical parameters. del Nido et al. [9] also demonstrated that the significant buffering capacity in a crystalloid solution can be effective in preserving myocardial adenosine triphosphate stores, improving post-arrest contractile function and minimizing myocardial necrosis.
Hachida et al. [10] indicated that the promotion of anaerobic glycolysis during ischaemic by HTK results in superior prolonged preservation of the energetic and contractile functions of the heart. Takeuchi et al. [11] also demonstrated that administration of the histidine-containing cardioplegia solution promotes anaerobic glycolysis and improves recovery of high-energy phosphates and contractile function in the hypertrophied myocardium.
HTK seems to preserve not only the myocardium but also the coronary artery endothelium. Saitoh [12] , in an experimental study with rat hearts, found that HTK protected the coronary vasculature which might lead to improved functional cardiac recovery. Yang [13] found that HTK is superior to the University of Wisconsin solution in protecting the endothelium-derived hyperpolarizing factor-mediated endothelium function in porcine small coronary arteries.
Although HTK has been used for several years, there are few studies comparing the effect with other widely established types of cardioplegia. We did not find any studies comparing HTK with the tepid blood cardioplegia in a range of complex cardiac procedures. Sakata et al. [1] used the HTK solution for valve surgery and found more spontaneous defibrillation and lower requirement of inotropic drugs compared with the use of cold blood cardioplegia. However, Fannelop et al. [14] in an experimental study found that cold blood cardioplegia provides better myocardial protection and preservation of left ventricular function than HTK in the early hours after declamping. Braathen et al. [15] in a randomized study measured markers of myocardial injury and demonstrated that HTK in elective mitral surgery protects the myocardium equally well compared to repetitive antegrade cold blood cardioplegia.
Braathen et al. [15] , however, found a significant increase in spontaneous ventricular fibrillation after the cross-clamp removal in patients receiving HTK. This is consistent with our anecdotal Absolute numbers (percentages).
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experience; however, it could not be demonstrated in our study as this was not quantified and recorded as data. An increase in fibrillation after cross-clamp removal has been linked to conduction disturbances associated with the inadequate intraoperative myocardial protection caused by heterogeneous reperfusion, oxidative stress and alteration of electrolyte concentration across the cell membranes and low adenosine triphophate levels. Despite this, Braathen et al. [15] showed that the increase in spontaneous ventricular fibrillation did not influence the release of myocardial enzymes compared with blood cardioplegia. In our study, in the non-propensity-matched analysis, there were significant differences between the two groups not only in the preoperative demographics, but more importantly in the complexity of the operations performed. This, in part, explains the differences in outcomes observed in the unmatched analysis, the complexity of the cases is much more similar, making the comparison more meaningful. It is also important to emphasize the low mortality achieved in a highly complex patient group with both forms of cardioplegia.
It is well known that lowering tissue temperature decreases myocardium metabolism significantly. The temperature of the blood cardioplegic solution given in our study was 28°C compared with 4°C in the HTK solution, making a comparison of the two cardioplegic solutions difficult. However, the aim of our study was to demonstrate that HTK was at least as safe as tepid blood cardioplegia. von Oppell et al. [16] stored cultures of human endothelium cells in different cardioplegic solutions and temperatures. According to their findings, the best available solution for hypothermic endothelium cell preservation is HTK. Its superiority at hypothermia appears to be due to the low chloride content of intracellular solutions and the additives histidine, tryptophan and KH-2-oxygluterate. It is also known that HTK should not be given in higher temperatures in clinical practice as this may result in stone heart.
The volumes of cardioplegia between the two groups are also different due to the means by which each agent provides myocardial protection. High volumes are required in the single dose method in order to assure complete cooling and distribution of cardioplegia to all myocardium territories. The volumes we used in this study were all based on recommendations from the company that manufactures HTK. Hot shot is normally not used in the HTK protocol. Our hot shot involves only retrograde perfusion with warm blood and therefore would not be harmful if given. However, other hot shot solutions may be different and would mix two complete different forms of cardioplegia (extracellular and intracellular), which would be harmful. According to Liu [17] , one single dose of HTK could cause haemodilution and hyponatraemia if the solution is sucked into the CPB circuit in the paediatric population. In our experience with adult patients, although the serum levels of sodium were generally lower in the postoperative period compared with the preoperative levels, this had minimal clinical impact as all the levels were within the normal reference range. We also noted that despite low levels of serum sodium, especially during the cardiopulmonary bypass time, the serum osmolality remained preserved. One could speculate that aggressive correction of the transient hyponatremia may, in fact, deleteriously increase the serum osmolality.
LIMITATIONS
The current study is retrospective in nature and is therefore subject to the inherent weaknesses of a retrospective analysis. These are only partly overcome by using a propensity-matched analysis as unquantifiable factors may indeed influence patient selection and outcomes. In addition, although operations were performed by multiple surgeons, this is a single-institution study, which limits its generalizability. Finally, the number of patients in the HTK group may not be enough to demonstrate any small but significant difference in major clinical endpoints. We were unable to analyse endpoints such as volume of cardioplegia delivered, cardiac rhythm after aortic cross-clamp removal, postoperative ejection fraction, wall motion abnormalities and cardiac enzyme levels as these data are not routinely collected at our centre. In many cases, postoperative investigations such as cardiac enzymes are not performed unless clinically indicated.
CONCLUSIONS
The use of Custodiol is convenient, simple and at least as safe as tepid blood cardioplegia for myocardial protection in complex cardiac operations. A randomized prospective comparison of myocardial protection strategies in complex cardiac surgery involving multiple institutions would provide further important information regarding its clinical efficacy. 
